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Abstract 
In host-pathogen interactions, often the host (attacked organism) defends itself by some 
toxic compound and the parasite, in turn, responds by producing an enzyme that inactivates 
that compound. In some cases, the host can respond by producing an inhibitor of that 
enzyme, which can be considered as a counter-counter defence. An example is provided by 
cephalosporins, β-lactamases and clavulanic acid (an inhibitor of β-lactamases). Here, we 
tackle the question under which conditions it pays, during evolution, to establish a counter-
counter defence rather than to intensify or widen the defence mechanisms. We establish a 
mathematical model describing this phenomenon, based on enzyme kinetics for 
competitive inhibition. We use an objective function based on Haber’s rule, which says 
that the toxic effect is proportional to the time integral of toxin concentration. The optimal 
allocation of defence and counter-counter defence can be calculated in an analytical way 
despite the nonlinearity in the underlying differential equation. The calculation provides a 
threshold value for the dissociation constant of the inhibitor. Only if the inhibition constant 
is below that threshold, that is, in the case of strong binding of the inhibitor, it pays to have 
a counter-counter defence. This theoretical prediction accounts for the observation that not 
for all defence mechanisms, a counter-counter defence exists. Our results should be of 
interest for computing optimal mixtures of β-lactam antibiotics and β-lactamase inhibitors 
such as sulbactam, as well as for plant-herbivore and other molecular-ecological 
interactions and to fight antibiotic resistance in general.  
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1. Introduction 
In many parasitic and trophic interactions, the host or prey organisms, respectively, defend 
themselves by toxic or malodorous compounds (defence chemicals) or other mechanisms 
such as pH changes, fever etc. Many of the attacking organisms, in turn, produce enzymes 
degrading the defence chemicals, which can be considered as a counter-defence (in the 
case of parasites often called evasion mechanisms). An example is the defence of human 
immune cells against the pathogenic fungus Candida albicans by producing superoxide 
radicals and other reactive oxygen species (ROS). C. albicans and many other pathogens, 
in turn, can detoxify the ROS by superoxide dismutases (SODs) (Frohner et al., 2008). For 
an overview of host-pathogen interactions between the human innate immune system and 
C. albicans, see Dühring et al. (2015). 
The question arises whether the host or prey can inhibit the evasion mechanisms by 
counter-counter defences. Does it pay, during evolution, to establish a counter-counter 
defence or is it more favourable to intensify or widen the defence mechanisms? 
Analogously, does it pay for the parasite or pathogen to establish a counter-defence or is it 
more favourable to intensify or widen the attack mechanisms? Are there examples of even 
higher levels of back-and-forth interactions?  
Such questions can be tackled in the framework of optimization approaches. Optimality 
principles have widely been used in explaining mechanisms and properties of living cells 
and organisms (cf. Heinrich and Schuster, 1996; Cornish-Bowden, 2016). For example, the 
optimal half-saturation constant of haemoglobin has been calculated by assuming that 
oxygen is bound and released in an optimal way (Willford et al., 1982). Waddell et al. 
(1999) could explain the ATP stoichiometry of glycolysis based on the principle of 
maximum ATP production rate (for other ATP-producing pathways, see Werner et al., 
2010). To analyse the usage of defence mechanisms in a mathematical way, the optimal 
defence hypothesis is helpful: It states that organisms allocate their defences in a way that 
maximises fitness (cf. Radhika et al., 2008). In the context of host-pathogen interactions, 
also dynamic (time-dependent) optimization was used (Dühring et al., 2017). 
In this paper, we use mathematical modelling and enzyme kinetics to study the benefit of 
counter-counter defences. We first review several examples of counter-counter defences in 
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various kingdoms of life (Section 2). In Section 3 and Appendix A, we present our 
mathematical model and analyse the effect of a substance inhibiting an enzyme that 
degrades a defence chemical. We compare this with an intensified defence. In that 
computation, we use analytical (rather than purely numerical) calculations as far as 
possible. 
 
2. Examples of counter defences and higher-order counter defences 
2.1. Fungi or Streptomyces and bacteria 
The constellation considered in this paper is illustrated in a general way in Fig. 1A and an 
example is shown in Fig. 1B.  
 
A) 
 
 
B) 
 
  
Fig. 1. Scheme of molecular host-pathogen interactions. A) General scheme including 
four levels of interaction (not all of them being always relevant). A similar constellation 
can also be found in predator-prey or plant-herbivore interactions. B) Specific example of 
Streptomyces clavuligerus and Salmonella bacteria interacting via β-lactam antibiotics, β-
lactamase and clavulanic acid. 
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An illustrative example is the following: Antibiotics represent a defence of certain fungi 
against attacks or competition for nutrients by bacteria. A special class is formed by the β-
lactam antibiotics, which are called that way because they harbour a β-lactam ring formed 
from cysteine and valine (Figure 1B). An example is provided by penicillins, such as those 
produced by Penicillium chrysogenum (cf. Christensen et al., 1995) and Aspergillus 
nidulans (Brakhage et al., 1994). Further groups of β-lactam antibiotics are the 
cephalosporins produced by fungi of the genus Acremonium, formerly known as 
Cephalosporium (Demain and Zhang, 1998) and the bacterium Streptomyces clavuligerus 
(Aharonowitz and Demain, 1978) as well as the synthetic carbapenems and semi-synthetic 
monobactams (Drawz and Bonomo, 2010). In medical applications, also semi-synthetic 
penicillin derivatives such as ampicillin and amoxicillin are widely used.  
As a counter-defence, many gram-negative bacteria, for example, Salmonella spp. and 
Klebsiella pneumoniae respond by secreting enzymes called β-lactamases. These enzymes 
are able to cleave the β-lactam ring, which makes these antibiotics inefficient because an 
essential mode of their action is that the ring opens at the target site. There are a wide 
variety of different β-lactamases such as metallo-β-lactamases (cf. Paterson et al., 2003).  
S. clavuligerus, in turn, produces clavulanic acid, which is structurally similar to the core 
unit of penicillins, with the sulfur atom replaced by oxygen (Figure 1B). In particular, it 
involves a β-lactam ring and can, therefore, act as a competitive inhibitor of β-lactamases. 
It shows little antimicrobial activity alone (Drawz and Bonomo, 2010). Rather, it provides 
a counter-counter defence. There are also synthetic pharmaceutical drugs that inhibit β-
lactamases (Mezes et al., 1982), for example, those distributed under the trade names 
sulbactam and tazobactam (Noguchi and Gill, 1988). For the above-mentioned reasons, 
these are often administered in combination with β-lactam antibiotics.  
The synthetic β-lactam antibiotic, carbapenem, is largely insusceptible to the classical β-
lactamases. However, it can be degraded by metallo-β-lactamases. These, in turn, are 
inhibited by aspergillomarasmine A produced by Aspergillus versicolor (King et al., 2014). 
It is unclear, though, why that fungus produces that counter-counter defence molecule 
because, to our knowledge, it has not been found that the fungus would produce β-lactam 
antibiotics. It may be hypothesized that it is useful in microbial communities involving 
producers of such antibiotics.   
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2.2. Plants and herbivores 
An example from the realm of plant-herbivore interactions is the following: The South-
American plant Psychotria viridis produces the hallucinogenic compound 
dimethyltryptamine as a defence chemical (cf. Soares et al., 2017). Higher animals 
produce, mainly in the brain, monoamine oxidase, which degrades tryptamines. P. viridis, 
in turn, also produces beta-carbolines (a.k.a. harmane compounds). These inhibit 
monoamine oxidase and, thus, represent a counter-counter defence.A more sophisticated 
example is the following: Glucosinolates are activated in Brassicaceae by the enzyme 
thioglucoside glucohydrolase (myrosinase). That activation leads to the toxic compound 
isothiocyanate. Some insects can degrade glucosinolates to less toxic nitriles. When the 
plants sense this degradation by insects, they form the nitriles themselves (Mumm et al., 
2008). This is paradoxical at first sight, but these substances prevent insect females from 
oviposition on the plants because they “assume” that there is a caterpillar already. Thus, 
the insects erroneously try to avoid intraspecific competition. This is a true counter-counter 
defence because it would not be effective if the counter-defence (degradation to nitriles by 
insects) were not present. 
 
2.3. Plants and pathogens 
Upon contact with pathogens, many plants (e.g. Arabidopsis) suppress the opening of their 
stomata by special mitogen-activated protein kinases (MAPK), e.g. MPK3 and MPK6. 
This is an example of plant immunity. The bacterial pathogen Pseudomonas syringae 
produces coronatine, an analogue of jasmonic acid, which suppresses these MAPKs. The 
counter-counter defence of the plant consists in the suppression of the jasmonate pathway 
by specific phosphatases, so that the reopening of stomata is suppressed (Mine et al., 
2017). 
There are further examples concerning the interaction of plants and pathogens, where at 
least one stage of interaction resides at the transcript level or genetic level (Pumplin and 
Voinnet, 2013, Hutin et al., 2015). For example, plant-pathogenic Xanthomonas bacteria 
use Transcription Activator-Like (TAL) effectors belonging to their type three secretion 
system (T3SS), which is an attack mechanism (Hutin et al., 2015). The TAL effectors bind 
to a programmable DNA-binding domain and induce specific plant genes, which suppress 
plant immunity and facilitate nutrient acquisition by the bacteria. Plants, in turn, have 
evolved defence strategies against the action of TAL effectors. One mechanism is to avoid 
binding by mutations, resulting in loss of susceptibility. Bacteria, in turn, may overcome 
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the effect of mismatches between TAL effectors and their cognate binding elements by 
aberrant-length repeats that can “loop out” when the TAL effector binds. This allows the 
recognition of target DNA sequences with a −1 nucleotide frame-shift. 
Hutin et al. (2015) speak of several rounds of interaction: the first to fourth rounds 
corresponding to attack, defence, counter defence and counter-counter defence, 
respectively. For the plant-bacteria example, the fourth round has not yet been observed in 
nature, but can be realized by human intervention. In view of application, this scenario is 
of great interest. As plant immunity is a defence mechanism, the TAL effectors (which 
suppress immunity) could even be considered both as an attack mechanism and as a 
counter defence. According to that interpretation, the third round described above would 
even be a (counter)3 defence. 
 
2.4. Macrophages and pathogens 
The levels of defence are not always clear-cut. Counter-counter defences may overlap with 
direct defences. For example, the Pra1 protein (counter-defence) of C. albicans interacts 
with human factor H, which is bound by C. albicans as an evasion mechanism (Zipfel et 
al., 2011). In human phagolysosomes, the pH is lowered considerably, which inhibits Pra1. 
However, lowering the pH is a broad defence against many proteins of C. albicans (Mayer 
et al., 2013; cf. Dühring et al., 2015). Interestingly, C. albicans and other fungal pathogens 
are able to increase the pH value from ~4 to ~7.5 by generation and export of ammonia 
(Vylkova, 2017). If acidification by the host is considered as a counter-counter defence, 
alkalinisation by the fungus would even be a (counter)3 defence.   
Another striking example of multi-layer defence interactions was discovered in the 
interaction between macrophages and bacterial pathogens like Yersinia pestis or 
Pseudomonas aeruginosa. As a first line of defence, macrophages phagocytose the 
attacking bacteria and, among other antibacterial strategies, are limiting glucose and other 
carbon sources within the phagolysosome (Weiss and Schaible, 2015). A key factor for 
pathogenicity of many bacteria such as Y. pestis is their ability to survive within 
macrophages by utilizing acetate and fatty acids (Li and Yang, 2008; Fukuto et al., 2010). 
This is enabled by the enzymes of the glyoxylate shunt, which circumvent the 
decarboxylation steps of the TCA cycle and are absent from most animals (Dolan and 
Welch, 2018). Michelucci et al. (2013) found that macrophages produce itaconic acid, 
which acts as a competitive inhibitor of the isocitrate lyase catalyzing the first reaction of 
the glyoxylate shunt. However, this counter-counter defence by macrophages is abolished 
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in bacterial pathogens like Y. pestis by a recently discovered degradation pathway of 
itaconate to pyruvate (Sasikaran et al., 2014), which represents a (counter)3 defence. 
Interestingly, the genes of the degradation pathway preferably occur in pathogens. This 
shows that the depth of defence interactions is certainly optimized by each organism 
depending on its survival strategy. 
 
3. Mathematical modelling: Defence chemical, degrading enzyme and inhibitor of the 
enzyme 
3.1. Basic differential equation  
We consider a defence chemical (toxin, e.g. penicillin) and an enzyme degrading that toxin 
(e.g. β-lactamase). We want to answer the question what is more beneficial for the toxin 
producer: producing more toxin or producing, in parallel, some inhibitor of the degrading 
enzyme (Fig. 1).  
To describe the rate of degradation of the toxin, we use the most widely used enzyme 
kinetics for competitive inhibition (cf. Cornish-Bowden, 2012): 
 
 d𝑇𝑇𝑇𝑇𝑇𝑇
d𝑡𝑡
= − 𝑉𝑉max𝑇𝑇𝑇𝑇𝑇𝑇
𝐾𝐾M(1+𝐼𝐼𝐼𝐼ℎ 𝐾𝐾I⁄ )+𝑇𝑇𝑇𝑇𝑇𝑇   (1) 
 
with the following symbols: Vmax and KM, maximal velocity and Michaelis constant of the 
enzyme, respectively; Tox and Inh, concentrations of toxin and inhibitor, respectively; KI, 
inhibition constant. Note that KI is a dissociation constant. Thus, the lower KI is, the more 
efficient the inhibitor will be. 
Importantly, Eq. (1) only describes the effect of competitive inhibitors if these act 
reversibly. Some inhibitors of β-lactamases such as avibactam (Ehmann et al., 2012; 
Lahiri, 2014) and boronic acid transition state analogues (Drawz and Bonomo, 2010) are 
indeed reversible, while clavulanic acid, sulbactam and tazobactam are irreversible 
inhibitors (Drawz and Bonomo, 2010). The former do not harbour a β-lactam ring. The 
latter bind, in a first phase, in a reversible way, so that the initial enzyme velocity can be 
described by Eq. (1). Thereafter, the enzyme-inhibitor complex is converted in a first-order 
reaction to an inactive form (so-called suicide inhibition). This conversion is usually 
described by an exponential time function (Labia et al., 1980).  
In the present paper, we consider reversible inhibition. As an approximation, Eq. (1) can 
even be used for irreversible inhibitors if inactivation proceeds very slowly. For example, 
for the β-lactam sulfon CP 45899 (being an irreversible β-lactamase inhibitor), the rate of 
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degradation is about 1000 times lower than that of penicillin degradation (Labia et al., 
1988) and can, thus, approximately be neglected.  
It is a plausible assumption that the toxin producer has a certain capacity C to invest into 
the production of toxin and/or inhibitor: 
 
Tox(0) + Inh = C. (2) 
 
The capacity C expresses in which amount the fungus can produce penicillin or structural 
analogues, measured by the concentration in which they can be maintained in the vicinity 
of the fungus. For simplicity’s sake, we assume that the synthesis of the toxin and its 
analogues imply the same costs per molecule to the producer. This assumption is justified 
in the case of a structurally similar competitive inhibitor. For example, penicillin and 
clavulanic acid are so similar in structure that their synthesis can be assumed to imply 
comparable costs. However, it is worth mentioning that these two substances are 
synthesized on two different pathways, with arginine being a precursor of clavulanic acid 
(Townsend, 2002). In the case of different costs, Eq. (2) can easily be modified by a 
weighting coefficient assigned to Inh. 
Eqs. (1) and (2) can be combined into: 
 
 d𝑇𝑇𝑇𝑇𝑇𝑇
d𝑡𝑡
= − 𝑉𝑉max𝑇𝑇𝑇𝑇𝑇𝑇
𝐾𝐾M�1+�𝐶𝐶−𝑇𝑇𝑇𝑇𝑇𝑇(0)� 𝐾𝐾I⁄ �+𝑇𝑇𝑇𝑇𝑇𝑇   (3) 
 
In some of the following equations, we use the effective Michaelis constant 
 
 𝐾𝐾𝑀𝑀′ = 𝐾𝐾𝑀𝑀 �1 + 𝐶𝐶−𝑇𝑇𝑇𝑇𝑇𝑇(0)𝐾𝐾𝐼𝐼 � . (4) 
 
While the inhibitor level remains constant in time, the toxin concentration decreases due to 
degradation (Fig. 2). In Eq. (3), the toxin concentration at time zero is relevant. 
 
3.2 The optimality criterion 
We now tackle the question what the optimal allocation to toxin and inhibitor is. If no 
inhibitor was produced, the initial toxin concentration would be maximum. However, also 
the degradation rate would be maximum. This is visualized in Fig. 2. The other extreme 
situation is where the entire capacity would be invested into the production of inhibitor. 
This is certainly useless because no toxic effect against the counterpart would remain.  
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We quantify the defence effect of the toxin by the time integral over Tox(t) from zero to 
infinity. In toxicology, this is known as Haber’s rule (cf. Connell et al., 2016). In 
pharmacokinetics, that time integral is called Area under the curve (AUC) (cf. Wagner et 
al., 1985; Lappin et al., 2006).  
We write the optimization principle as 
 
 maximize ∫ 𝑇𝑇𝑇𝑇𝑇𝑇(𝑡𝑡)∞0 d𝑡𝑡 , (5) 
 
where the initial value Tox(0) is the variable of optimization.  
The AUC is finite only when Tox(t) is a monotonic decreasing function approaching zero 
and decreases fast enough. For example, the time integral over an exponentially decreasing 
function is finite, while the time integral over a hyperbolic function 1/t is infinite. 
Integrating up to infinite times is a mathematical abstraction. In reality, the effect ends at 
finite times, of course. However, the ‘tail’ of the integral can often be neglected.      
 
4. Results 
4.1. Solution by linear approximation  
In some equations (especially longer ones), we will use the abbreviations 𝑇𝑇𝑇𝑇𝑇𝑇(𝑡𝑡) = 𝑇𝑇 and 
𝑇𝑇𝑇𝑇𝑇𝑇(0) = 𝑇𝑇0. To get a preliminary idea of the solution, we first derive an approximative 
solution by linearization and below, we solve the nonlinear problem. For the 
approximation, we assume that T is considerably lower than the Michaelis constant. This is 
particularly well justified for long times (note that the integral (5) spans infinite times), 
because then the β-lactamases degrade the penicillin to low levels. Under this assumption, 
we can simplify the Michaelis-Menten kinetics to linear kinetics: 
 
 d𝑇𝑇
d𝑡𝑡
= − 𝑘𝑘∗𝑇𝑇
1+(𝐶𝐶−𝑇𝑇0) 𝐾𝐾I⁄   , (6) 
 
where we abbreviate the ratio Vmax/KM by k. The time course of the penicillin concentration 
then decreases in an exponential way: 
 
 𝑇𝑇 = 𝑇𝑇0 ∗ 𝑒𝑒𝑇𝑇𝑒𝑒 �− 𝑘𝑘1+(𝐶𝐶−𝑇𝑇0) 𝐾𝐾I⁄ � 𝑡𝑡 . (7) 
 
The time course is illustrated in Fig. 2.  
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Fig. 2. Time course of toxin concentration without inhibitor and with varying 
concentrations of the inhibitor of the enzyme degrading the toxin. Curves were 
computed by approximation (3), which leads to exponential function (4). The curves 
correspond to increasing inhibitor concentrations, from the curve starting with the highest 
initial value corresponding to the case without inhibitor up to the lowest curve, where I = C 
= 10, with a step size of 1. Red curve: optimal case. For the bottom curve, the toxin 
concentration is zero all the time because all the capacity is invested into the inhibitor. 
Parameter values: k = 0.1; C = 10;  Ki = 0.5.  
 
The integral can be calculated analytically: 
 
 ∫ 𝑇𝑇
∞
0
d𝑡𝑡 = 𝑇𝑇0 ∫ 𝑒𝑒𝑇𝑇𝑒𝑒 �− 𝑘𝑘1+(𝐶𝐶−𝑇𝑇0) 𝐾𝐾I⁄ � 𝑡𝑡 d𝑡𝑡∞0  
 
 = 𝑇𝑇0
𝑘𝑘
(1 + (𝐶𝐶 − 𝑇𝑇0) 𝐾𝐾I⁄ ) . (8) 
 
We can multiply this expression by KI *k without changing the position of the maximum, 
so that the maximization principle reads 
 
 maximize 𝑇𝑇0(𝐾𝐾I + 𝐶𝐶 − 𝑇𝑇0) . (9) 
 
This is a quadratic function in T0 (Fig. 3) and, thus, has indeed a maximum, which can be 
calculated by differentiation. This gives  
 
 𝑇𝑇0,𝑇𝑇𝑜𝑜𝑡𝑡 = 𝐾𝐾I+𝐶𝐶2  . (10) 
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Fig. 3. Integrated toxic effect (objective function value) vs. initial toxin concentration, 
Tox(0), as computed by the approximative function (9). Note that Tox(0) = C−Inh. 
Dashed red line, maximum at Tox(0) = (KI+C)/2 = 5.25. Parameter values are as in Fig. 2. 
 
Now we can distinguish two cases: 
 
(i) KI < C (strong binding of the inhibitor). Then the benefit-to-cost ratio is high because 
producing the inhibitor provides a high benefit. The maximum is in the interior of the 
interval [0, C]. It pays to invest part of C into the counter-counter defence (e.g. clavulanic 
acid). In the extreme case where KI is nearly zero (very efficient inhibitor), about half of C 
should be invested into the defence and half into the counter-counter defence. 
(ii) KI > C (weak binding of the inhibitor, or low benefit-to-cost ratio): Then the maximum 
lies above C and, thus, cannot be reached. It does not pay to invest part of C into the 
counter-counter defence. It is better to invest C fully into toxin (e.g. penicillin). This is 
because the counter-counter defence is too weak. 
 
4.2. Exact analytical solution  
Eq. (1) cannot be solved analytically in a way that Tox could be written as a function of 
time. Nevertheless, the improper integral occurring in Eq. (5) can be calculated analytically 
for the case where the substance (toxin in our case) is degraded by a Michaelis-Menten 
enzyme (cf. Wagner et al., 1985). To that end, Eq. (6) is rearranged as 
 
 𝑇𝑇𝑇𝑇𝑇𝑇d𝑡𝑡 = − 𝐾𝐾M′
𝑉𝑉max
d𝑇𝑇𝑇𝑇𝑇𝑇 − 𝑇𝑇𝑇𝑇𝑇𝑇
𝑉𝑉max
d𝑇𝑇𝑇𝑇𝑇𝑇 (11) 
 
where the abbreviation (4) is used. Integration gives 
 
 ∫ 𝑇𝑇𝑇𝑇𝑇𝑇d𝑡𝑡∞0 = −𝐾𝐾M′ 𝑇𝑇𝑇𝑇𝑇𝑇𝑉𝑉max � 0𝑇𝑇0 − 𝑇𝑇𝑇𝑇𝑇𝑇22𝑉𝑉max� 0𝑇𝑇0 
12 
 
 = 1
𝑉𝑉max
�𝐾𝐾M
′ 𝑇𝑇0 + 𝑇𝑇022 � . (12) 
 
Note that the lower and upper bounds in the integrals over Tox are T0 and 0, respectively, 
because the curve proceeds between these two values. Like the function in Eq. (9), the 
function in Eq. (12) is quadratic in T0 (Fig. 5). It is consistent with the objective function 
(9) in the approximative solution, as can be seen by assuming T0 << KM, which implies 
T0 << 𝐾𝐾𝑀𝑀′  . Thus, we can neglect, in that case, the term 𝑇𝑇02 2⁄  in the parenthesis in Eq. (12). 
Under consideration of the abbreviation (4), this leads to an objective function that is 
proportional (and, thus, equivalent) to the one in Eq. (9). An alternative calculation of the 
improper integral is presented in the Appendix. 
Fig. 4 shows the resulting time course. The curves starting at higher toxin concentrations 
(that is, for which the inhibitor concentration is lower) decrease, at the outset, almost with 
a constant slope, unlike in the approximative solution. This is because the parameter values 
were chosen such that the enzyme operates near to saturation first, so that the degradation 
velocity is nearly constant. This can also be seen from Eq. (A3) in the Appendix. Since the 
logarithmic function increases less than the linear function, the term T dominates the term 
lnT for large T. Thus, T and time are then correlated nearly linearly. Later (for larger time 
values), when the concentration has become so low that the enzyme operates in the linear 
range, it decreases in an exponential way, like in the approximative solution. 
 
 
Fig. 4. Time course of toxin concentration for the exact solution. The time course can 
be computed analytically by Eq. (A3) in the Appendix or numerically using the kinetics for 
competitive inhibition (1). The curves correspond to increasing inhibitor concentrations, 
from the curve starting with the highest initial value corresponding to the case without 
inhibitor up to the lowest curve, where I = C = 10, with a step size of 1. Red curve: optimal 
case. Parameter values: Vmax = 0.1; Km = 1; C = 10;  Ki = 0.5. 
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Returning now to the general case of not necessarily small T0 values, we calculate the T0 
for which the function in Eq. (9) is maximum. By differentiation of the r.h.s. of Eq. (12), 
we obtain the position of the maximum: 
 
 𝑇𝑇0,𝑇𝑇𝑜𝑜𝑡𝑡 = 𝐾𝐾𝑀𝑀(𝐾𝐾I+𝐶𝐶)2𝐾𝐾𝑀𝑀−𝐾𝐾𝐼𝐼  . (13) 
 
It can be seen that there is no optimum at a positive T0 value if KI > 2KM, in which case the 
inhibitor is very weak.   
By comparing the optimal T0 value with C, we can consider three different cases: 
 
(i) 𝐾𝐾𝐼𝐼 < 𝐾𝐾𝑀𝑀𝐶𝐶 (𝐾𝐾𝑀𝑀 + 𝐶𝐶)⁄  (strong binding of the inhibitor). The benefit-to-cost ratio is high 
and the maximum lies in the interior of the interval [0, C] (Fig. 5). It pays to invest part of 
C into the counter-counter defence. Like in the linearized case, in the limit 𝐾𝐾𝐼𝐼 → 0, the 
optimal T0 tends to C/2, implying that about half of C should be invested into the defence 
and half into the counter-counter defence.        
(ii) 2𝐾𝐾𝑀𝑀 > 𝐾𝐾𝐼𝐼 > 𝐾𝐾𝑀𝑀𝐶𝐶 (𝐾𝐾𝑀𝑀 + 𝐶𝐶)⁄  (weak binding of the inhibitor, or low benefit-to-cost 
ratio): Then the maximum lies above C and, thus, cannot be reached.  
(iii) 𝐾𝐾𝐼𝐼 > 2𝐾𝐾𝑀𝑀. There is no optimum at a positive T0 value. Note that this case does not 
occur in the linearized case because the kinetics can only be linearized when the KM value 
is high.  
 
 
Fig. 5. Integrated toxic effect (objective function value) vs. initial toxin concentration, 
Tox(0), for the exact solution (12). Note that Tox(0) = C−Inh. Dashed red line, maximum 
Tox(0) = 7.0. Parameter values as in Fig. 4. 
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Both in cases (ii) and (iii), it is better to invest C fully into toxin (e.g. penicillin) than to 
invest part of C into the counter-counter defence. This is because the counter-counter 
defence is too weak. 
 
 
Fig. 6. Comparison of results for the optimal initial toxin concentration between the 
approximative and exact solutions. Dashed red line, linearized model; blue solid curve, 
nonlinear model. Parameter values: Vmax = 0.1; Km = 1; C = 10.  
 
Fig. 6 shows a comparison between the exact and linearized solutions. It can be seen that 
the exact curve hits the upper limit value of 10 at a KI value of about 0.9. This can be 
calculated by 𝐾𝐾𝑀𝑀𝐶𝐶 (𝐾𝐾𝑀𝑀 + 𝐶𝐶)⁄ = 10 (1 + 10) = 0.909⁄ . For KI values larger than this 
threshold, the optimal Tox(0) value equals C. The curve corresponding to the linearized 
case hits the upper limit value at KI = 10. It turns out that the linearization yields a good 
approximation only for very low KI values. This is because KM is quite low; for larger 
values the approximation gets better (not shown). 
 
5. Discussion 
In this paper, we have analysed, by mathematical modelling, the defence, counter-defence 
and counter-counter defence in the interaction between fungal pathogens and the human 
host. As an illustrative example, we have studied β-lactam antibiotics (defence), β-
lactamases (counter defence) and clavulanic acid (counter-counter defence). The 
calculations can be applied to any interaction among two opposing organisms, in which a 
toxin is degraded by an enzyme that is, in turn, inactivated by a competitive inhibitor. 
The optimal allocation can be calculated in an analytical way in spite of the nonlinearity of 
the underlying differential equation. The calculation provides a threshold value for the 
inhibition constant: 𝐾𝐾𝑀𝑀𝐶𝐶 (𝐾𝐾𝑀𝑀 + 𝐶𝐶)⁄ , where KM is the Michaelis constant of the enzyme 
and C denotes the total capacity that can be invested by the host in the toxin and the 
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inhibitor. Only if the inhibition constant is below this threshold, that is, in the case of 
strong binding of the inhibitor, it pays to have a counter-counter defence.  
This theoretical prediction accounts for the observation that not for all defence 
mechanisms, a counter-counter defence exists. It can be assumed that host organisms that 
do not exhibit such mechanisms are not capable of producing inhibitors that would be 
efficient enough to fulfil the above-mentioned criterion. This explains well why some 
fungi do produce β-lactamase inhibitors while others do not. 
Our results are likely to have very useful applications in pharmacy. They allow one to 
compute the optimal mixture in the dosage of β-lactam antibiotics and β-lactamase 
inhibitor such as sulbactam and tazobactam in combination pharmaceuticals.  
It is interesting that the total effect of a toxin in the case of permanent degradation by 
Michaelis-Menten type enzyme, as calculated according to Haber’s rule, can be calculated 
analytically (Wagner et al., 1985). In the Supplement, we have presented an alternative 
analytical calculation, which is based on the idea to swap variables, as used already by 
Michaelis and Menten (1913). 
The use of clavulanic acid, which has a similar structure as the β-lactam antibiotics, by 
Streptomyces clavuligerus is interesting also in view of the question why many defence 
chemicals (such as glucosinolates in Brassicaceae plants) occur as mixtures of several 
similar compounds. One might argue that mixtures widen the effect. On the other hand, the 
counterpart organism could respond by degrading enzymes with broad substrate specificity 
in a way that all the defence chemicals in the mixture are inactivated. However, the 
advantage of mixtures may be that some chemicals may act as competitive inhibitors of 
those enzymes. Moreover, broad substrate specificity often implies larger Km values, so 
that it is easier to synthesize an inhibitor that corresponds to case (i) in Subsection 4.2.  
The results are of general relevance. They show that it depends on certain conditions 
whether a counter-counter defence is useful or whether it is better to intensify the defence. 
It is plausible to assume that the results can be generalized in a qualitative way to cases of 
counter-counter defence other than inhibitors of degrading enzymes. As mentioned in the 
Introduction, also the interplay at the level of attack and counter defence can be studied in 
a similar way. Our results suggest that it is only worth establishing a counter-counter 
defence (or counter defence) rather than intensifying an existing defence (respectively 
attack) if the new level is more effective than a critical value. In the case of enzyme 
inhibitors, effectiveness can be measured by the inhibition constant.   
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The presented model can be a guideline in searching for hitherto unknown effectors, for 
example, inhibitors of superoxide dismutases (SODs) or secreted aspartyl proteases 
(SAPs). However, since the substrate of SODs are reactive oxygen species (ROS), the 
question arises whether competitive inhibitors for that exist.  
In future extensions of the study, it is worth including the host microbiome. It may well be 
that some bacteria produce antifungal substances that can, from the host’s viewpoint, be 
considered as a defence or counter-counter defence. Further, this extends the constellation 
of host-pathogen interactions (Fig. 1) to more than two organisms. This enables an 
investigation of communities where organisms show a division of labour between defence 
and counter-counter defence mechanisms against a pathogen or competitor. 
A more sophisticated model should include the reliability of the effector. As each level 
depends on the lower levels, an effector becomes useless if the effector on the next-lower 
level is qualitatively changed. This may shift the trend away from establishing new levels 
towards intensifying existing effects on lower levels. 
As the present model is based on Haber’s rule, the objective function also involves 
contributions from time periods in which the toxin concentration is low. A more realistic 
approach should consider that there is a critical threshold of the toxin concentration below 
which the defence chemical has no effect at all. Moreover, it is worth analysing the effect 
not only of a change in the inhibition constant but also in the capacity C. For example, 
counter-counter defence are induced upon confrontation with the counterpart, which may 
increase the capacity allocated to the defence. 
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Appendix: Alternative analytical solution 
As has been shown already by Michaelis and Menten (1913) in their pioneering paper on 
enzyme kinetics, such equations can be solved by exchanging the dependent and 
independent variables, that is, in our case, Tox and time. We obtain 
 
 ∫ 𝐾𝐾𝑀𝑀
′ +𝑇𝑇
𝑇𝑇
𝑑𝑑𝑇𝑇
𝑇𝑇
𝑇𝑇0 = −∫ 𝑉𝑉𝑚𝑚𝑚𝑚𝑇𝑇𝑑𝑑𝑡𝑡𝑡𝑡0  . (A1) 
 
 𝐾𝐾𝑀𝑀′ ln 𝑇𝑇𝑇𝑇0 + 𝑇𝑇 − 𝑇𝑇0 = −𝑉𝑉𝑚𝑚𝑚𝑚𝑇𝑇𝑡𝑡. (A2) 
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 𝑡𝑡 = 1
𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚
(𝐾𝐾𝑀𝑀′ (ln𝑇𝑇0 − ln𝑇𝑇) + 𝑇𝑇0 − 𝑇𝑇). (A3) 
  
Thus, we can formally express time as a function of the toxin concentration. Although this 
function cannot be inverted analytically, it can be used to plot Tox as a function of time, by 
swapping coordinate axes (Fig. 4). An alternative way of computing this function is by 
integrating the differential equation (1) numerically.   
For computing the integral (5), we make use of the fact that the area under the curve T(t) is 
the same as the area under the curve t(T). Therefore, we can calculate the integral ∫ 𝑡𝑡𝑑𝑑𝑇𝑇𝑇𝑇00  
using Eq. (A3). 
 
 ∫ 𝑡𝑡
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 = 𝑇𝑇0�2𝐾𝐾𝑀𝑀′ +𝑇𝑇0�
2𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚
 
 
 =  
𝑇𝑇0�2𝐾𝐾𝑀𝑀�1+
𝐶𝐶−𝑇𝑇0
𝐾𝐾𝐼𝐼
�+𝑇𝑇0�
2𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚
 .  (A4) 
 
This resulting term is equivalent to that obtained in Eq. (12).  
  
 
 
 
 
 
